[go: up one dir, main page]

WO2000035414A1 - Sunscreen composition - Google Patents

Sunscreen composition

Info

Publication number
WO2000035414A1
WO2000035414A1 PCT/EP1999/008322 EP9908322W WO0035414A1 WO 2000035414 A1 WO2000035414 A1 WO 2000035414A1 EP 9908322 W EP9908322 W EP 9908322W WO 0035414 A1 WO0035414 A1 WO 0035414A1
Authority
WO
WIPO (PCT)
Prior art keywords
sunscreen
composition
skin
stearic acid
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/008322
Other languages
French (fr)
Inventor
Govindarajan Raman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hindustan Unilever Ltd
Unilever NV
Original Assignee
Hindustan Lever Ltd
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hindustan Lever Ltd, Unilever NV filed Critical Hindustan Lever Ltd
Priority to KR1020017007506A priority Critical patent/KR20010089579A/en
Priority to JP2000587735A priority patent/JP2002532402A/en
Priority to AU16509/00A priority patent/AU746501B2/en
Priority to BR9916226-1A priority patent/BR9916226A/en
Publication of WO2000035414A1 publication Critical patent/WO2000035414A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35Ketones, e.g. benzophenone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to an improved cosmetic sunscreen composition for topical application to human skin to provide enhanced protection from sunlight and a process for preparing the same .
  • Melanin is the black pigment synthesised by the action of the enzyme tyrosinase on the amino acid tyrosine. The reaction takes place in organelles called melanosomes contained within cells called melanocytes . Melanocytes transfer melanosomes with melanin to neighbouring keratinocytes which harbour these organelles till they are themselves shed from the body from the superficial layers of the skin. The intensity of the skin colour is directly related to the number, the size, melanin content, the rate of formation and transfer of melanosomes to keratinocytes. Melanin is also an important protectant of skin and tissues beneath the skin as it has the capacity to absorb incident ultraviolet light.
  • UV-A having a wavelength of from about 320 to 400 nm which gives a tanning effect without inflammation
  • UV-B having a wavelength of from about 290-320 nm which is responsible for erythema (sunburn) and eventually for tanning
  • UV-C having a wavelength of from about 200-290 nm, normally absorbed by the ozone layer in the earth's atmosphere, but which is potentially very damaging to the skin.
  • Melanogenesis and pigmentation of the skin are closely related responses to irradiation by UV light. The photobiological changes that cause erythema also lead to melanogenesis and increased pigmentation.
  • the skin has to be protected broadly across the UV-A range of from about 320-400 nm. We have found that by careful selection of sunscreens we can protect the skin against the darkening effects of radiation.
  • GB 1 370 236 discloses a skin lightening composition containing niacin and the method by which it effects skin lightening is by retardation of melanin dispersion or distribution into the epidermis.
  • GB 1 533 119 discloses that niacinamide is useful as a skin lightening agent without causing skin flushing reaction due to vasodialation of blood vessels which is often associated with niacin.
  • GB 2230186 discloses that addition of a silicone compound to the composition containing a mixture of sunscreen and niacinamide improves the coverage of the cream on the skin for improved protection against the UV light.
  • compositions containing sunscreens are enhanced when the sunscreen is dissolved in an oil phase. More specifically the applicants have found that the use of the sunscreen dissolved in oil phase has improved sunscreen efficacy than that which may be obtained otherwise by using the sunscreen at substantially higher levels. Thus, the amount of sunscreen required to achieve the same UV protection is reduced by the present invention.
  • the present invention provides a topical cosmetic sunscreen composition
  • a topical cosmetic sunscreen composition comprising from (i) 0.1 to 10% by weight of the composition of an ultra-violet radiation absorbing sunscreen dissolved in an oil; and (ii) a cosmetically acceptable vehicle.
  • the composition is preferably obtained by the process below provided by the present invention.
  • the present invention also provides a process for the preparation of a cosmetic sunscreen composition comprising the steps of :
  • the dissolved sunscreen may be homogenised with the neutralised stearic acid and subsequently blended with the vehicle (and other ingredients) of the composition. It is preferable however for the neutralised stearic acid and vehicle to be blended together and the dissolved sunscreen subsequently to be added to the blend as this has been found to give a composition with an optimal sunscreen effect.
  • the stearic acid is neutralised with an alkali such as potassium hydroxide. It is preferred that prior to step (ii) the stearic acid is melted at a temperature above 70°C.
  • the sunscreen is preferably chosen from 4-tertiary butyl-4' - methoxy dibenzoylindethane, available under the trade name PARSOL 1789 ex Givaudan, 2 -ethyl hexyl methoxy cinnamate, available under the trade name PARSOL MCX ex Givaudan or mixtures of the two sunscreen compounds.
  • the composition comprises 0.1 to 10% by weight of the composition and preferably 0.1 to 5% by weight of the composition of a sunscreen compound.
  • the oil can be mineral oil, vegetable oil or from any other source but is preferably in the liquid state at temperatures greater than 20°C.
  • the oil can be selected from mineral oil, ground nut oil, sunflower oil, safflower oil, til oil or mixtures thereof. But if the preferred process is used where the sunscreens are dissolved in the oil phase and these are subsequently added to the blended neutralised stearic acid and vehicle in the water phase, then the oil need not be one which is in the liquid state at temperatures above 20 °C. Suitable oils in these circumstances include isopropyl myristate .
  • the stearic acid is first melted at 70°C and then neutralised with aqueous potassium hydroxide to which sunscreen dissolved in oil is added after the emulsion has cooled to a temperature of less than 50°C.
  • This emulsion forms the base for all other ingredients. All other ingredients may then be homogenised with the base. In a preferred embodiment, these other ingredients are blended with stearic acid/water phase prior to homogenisation with the sunscreen/oil phase.
  • the composition of the invention may optionally comprise from 0.1 to 10%, preferably 0.5 to 5% by weight of one or more skin whitening agents.
  • the skin whitening agent is preferably chosen from niacin, niacinamide or a precursor thereof that is capable of releasing niacinamide on the skin.
  • Niacinamide is the amide of niacin and is also known as nicotinamide or pyridine-3-carboxylic acid.
  • An example of a compound which is a niacinamide precursor is niacinamide ascorbate.
  • Other suitable skin whitening agents include extracts of placenta, hydroquinone and derivatives (eg.
  • the vehicle which forms part of the cosmetic composition is one or more substances which are mutually compatible with the sunscreen and if present, the skin whitening agent, and does not harm the skin.
  • the vehicle can act as a diluent, dispersant or carrier for the other ingredients of the composition, and is therefore intended to ensure that they can be readily applied to and distributed evenly over the skin at an appropriate concentration.
  • compositions according to the invention can include water, powder absorbents, binders and carriers and liquids such as emollients, propellants, solvents, humectants and thickeners.
  • compositions according to the invention can be prepared for topical application to the skin in the form of conventional product types such as creams, lotions, ointments and aerosol products .
  • Example 2a Cream containing no sunscreen or niacinamide
  • Example 2b Creams prepared by the conventional process described above where in the sunscreens
  • Example 2c Creams prepared as in Example 2b but containing double the level of sunscreens
  • Example 2d Creams prepared according to the invention as described above in which sunscreens (Parsol 1789 at 0.4% and Parsol MCX at 1.2% by weight of the composition) dissolved in mineral oil was added. Niacinamide at 1.0% was added.
  • the frame with tapes was placed on a UV source such that the sticky surface of the tape faces downwards.
  • a UV filter was placed over the source to ensure a UV light of constant intensity in the range of 240-350 nm. was obtained.
  • a thin uniform film of a fluorescent dye CBS-X which has an absorption maximum of 368 nm and emission maximum of 406 and 426 nm, as a 2% solution in 1:1 gycerol :water was taken between two cover slips and placed on the non glue side of the tape. This enabled the emission of a visible light wherever there was UV light coming through the tape which was picked up by the video camera with a macroscopic lens (6X) was used. Thus wherever sunscreen was present UV light would be blocked and the fluorescer would not be excited thus giving a black area.
  • the video camera was connected to a computer with a frame grabber card and using this images were stored.
  • Optimas image analysis software it was possible to quantify the difference in the amount of UV light passing through the tape. The lesser the intensity the better will be the UV blockage and thus better sunscreen efficacy.
  • the actual amount of UV A and UV B transmitted was also measured using specific probes for UV A and UV B.
  • Table 1 shows that the efficacy of sunscreen in the formulation prepared according to the invention will be superior to creams prepared by the conventional process and is comparable to creams having double the amount of sunscreen in a formulation prepared according the conventional process.
  • creams were fielded in a double blind skin lightening clinical trial.
  • 20 volunteers were selected who applied 0.75 g of creams prepared according to the invention as described in example 1 but using 2% isopropyl myristate (instead of mineral oil) as the oil phase (3a) , or creams prepared according to the conventional process (2b) , on one of their forearms twice daily.
  • the other forearm was maintained as unapplied control.
  • the skin tone was visually evaluated on a 10 point scale one day prior to application and after 8 weeks of application.
  • the data presented in Table 3 is a change in the score after 8 weeks of application. A negative score indicates a lighter skin tone as compared to the control .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

A topical cosmetic sunscreen composition comprising (a) from 0.1 to 10% by weight of the composition of an ultra-violet radiation absorbing sunscreen dissolved in an oil; and (b) a cosmetically acceptable vehicle. A process for preparing such a composition is also described. The inventive composition has improved sunscreen efficacy.

Description

SUNSCREEN COMPOSITION
Technical Field of the Invention
The present invention relates to an improved cosmetic sunscreen composition for topical application to human skin to provide enhanced protection from sunlight and a process for preparing the same .
Background and Prior Art
Melanin is the black pigment synthesised by the action of the enzyme tyrosinase on the amino acid tyrosine. The reaction takes place in organelles called melanosomes contained within cells called melanocytes . Melanocytes transfer melanosomes with melanin to neighbouring keratinocytes which harbour these organelles till they are themselves shed from the body from the superficial layers of the skin. The intensity of the skin colour is directly related to the number, the size, melanin content, the rate of formation and transfer of melanosomes to keratinocytes. Melanin is also an important protectant of skin and tissues beneath the skin as it has the capacity to absorb incident ultraviolet light.
The UV range is divided into three regions, UV-A, having a wavelength of from about 320 to 400 nm which gives a tanning effect without inflammation; UV-B, having a wavelength of from about 290-320 nm which is responsible for erythema (sunburn) and eventually for tanning; and UV-C, having a wavelength of from about 200-290 nm, normally absorbed by the ozone layer in the earth's atmosphere, but which is potentially very damaging to the skin. Melanogenesis and pigmentation of the skin are closely related responses to irradiation by UV light. The photobiological changes that cause erythema also lead to melanogenesis and increased pigmentation. Hence exposure to sunlight leads to darkening of the skin by immediate pigment darkening of already formed melanin, and also by formation of new melanin. Many skin compositions are formulated for the purpose of maintaining the colour of the skin against darkening following exposure to ultra-violet light. These compositions have been based on materials which deflect and scatter incident ultra-violet light of the wavelength which produce burning and tanning of the skin or which absorb this light.
To prevent darkening of existing melanin and formation of new melanin, the skin has to be protected broadly across the UV-A range of from about 320-400 nm. We have found that by careful selection of sunscreens we can protect the skin against the darkening effects of radiation.
GB 1 370 236 discloses a skin lightening composition containing niacin and the method by which it effects skin lightening is by retardation of melanin dispersion or distribution into the epidermis.
GB 1 533 119 discloses that niacinamide is useful as a skin lightening agent without causing skin flushing reaction due to vasodialation of blood vessels which is often associated with niacin.
GB 2230186 discloses that addition of a silicone compound to the composition containing a mixture of sunscreen and niacinamide improves the coverage of the cream on the skin for improved protection against the UV light.
The applicants have found that the protection of skin against UV light by compositions containing sunscreens is enhanced when the sunscreen is dissolved in an oil phase. More specifically the applicants have found that the use of the sunscreen dissolved in oil phase has improved sunscreen efficacy than that which may be obtained otherwise by using the sunscreen at substantially higher levels. Thus, the amount of sunscreen required to achieve the same UV protection is reduced by the present invention.
Accordingly the present invention provides a topical cosmetic sunscreen composition comprising from (i) 0.1 to 10% by weight of the composition of an ultra-violet radiation absorbing sunscreen dissolved in an oil; and (ii) a cosmetically acceptable vehicle. The composition is preferably obtained by the process below provided by the present invention.
The present invention also provides a process for the preparation of a cosmetic sunscreen composition comprising the steps of :
(i) dissolving 0.1 to 10% by weight of the composition of an ultra-violet radiation absorbing sunscreen in an oil phase;
(ii) neutralising stearic acid in a water phase; and (iii) homogenising the dissolved sunscreen with the neutralised stearic acid and a cosmetically acceptable vehicle .
The dissolved sunscreen may be homogenised with the neutralised stearic acid and subsequently blended with the vehicle (and other ingredients) of the composition. It is preferable however for the neutralised stearic acid and vehicle to be blended together and the dissolved sunscreen subsequently to be added to the blend as this has been found to give a composition with an optimal sunscreen effect.
Preferably the stearic acid is neutralised with an alkali such as potassium hydroxide. It is preferred that prior to step (ii) the stearic acid is melted at a temperature above 70°C.
The sunscreen is preferably chosen from 4-tertiary butyl-4' - methoxy dibenzoylernethane, available under the trade name PARSOL 1789 ex Givaudan, 2 -ethyl hexyl methoxy cinnamate, available under the trade name PARSOL MCX ex Givaudan or mixtures of the two sunscreen compounds. The composition comprises 0.1 to 10% by weight of the composition and preferably 0.1 to 5% by weight of the composition of a sunscreen compound.
The oil can be mineral oil, vegetable oil or from any other source but is preferably in the liquid state at temperatures greater than 20°C. The oil can be selected from mineral oil, ground nut oil, sunflower oil, safflower oil, til oil or mixtures thereof. But if the preferred process is used where the sunscreens are dissolved in the oil phase and these are subsequently added to the blended neutralised stearic acid and vehicle in the water phase, then the oil need not be one which is in the liquid state at temperatures above 20 °C. Suitable oils in these circumstances include isopropyl myristate .
In a one embodiment the stearic acid is first melted at 70°C and then neutralised with aqueous potassium hydroxide to which sunscreen dissolved in oil is added after the emulsion has cooled to a temperature of less than 50°C. This emulsion forms the base for all other ingredients. All other ingredients may then be homogenised with the base. In a preferred embodiment, these other ingredients are blended with stearic acid/water phase prior to homogenisation with the sunscreen/oil phase.
The composition of the invention may optionally comprise from 0.1 to 10%, preferably 0.5 to 5% by weight of one or more skin whitening agents. The skin whitening agent is preferably chosen from niacin, niacinamide or a precursor thereof that is capable of releasing niacinamide on the skin. Niacinamide is the amide of niacin and is also known as nicotinamide or pyridine-3-carboxylic acid. An example of a compound which is a niacinamide precursor is niacinamide ascorbate. Other suitable skin whitening agents include extracts of placenta, hydroquinone and derivatives (eg. arbutin) , kojic acid, dicarboxylic acids (azelaic acid, sebacic acid) , represented by the formula HOOC- (CxHy) -COOH where x=4 to 20 and y=6 to 40, ascorbic acid and derivatives thereof, hydroxy acids (lactic acid, glycolic acid, malic acid, tartaric acid etc) , ferulic acid, retinol and derivatives or any other known skin whitening compounds. The vehicle which forms part of the cosmetic composition is one or more substances which are mutually compatible with the sunscreen and if present, the skin whitening agent, and does not harm the skin. The vehicle can act as a diluent, dispersant or carrier for the other ingredients of the composition, and is therefore intended to ensure that they can be readily applied to and distributed evenly over the skin at an appropriate concentration.
The vehicles that can be used in compositions according to the invention can include water, powder absorbents, binders and carriers and liquids such as emollients, propellants, solvents, humectants and thickeners.
Compositions according to the invention can be prepared for topical application to the skin in the form of conventional product types such as creams, lotions, ointments and aerosol products .
The invention is further illustrated by reference to the following examples.
Examples
Example 1:
Process for preparing the composition according to the invention:
60g of water along with 0.48g of potassium hydroxide was heated to 70°C in the main mixer. 16g of stearic acid, 4.4g Isopropyl palmitate, 0.15g propyl paraben was heated to 70°C in the side vessel and was added to the main mixer and mixed well. To this other conventional ingredients, lg niacinamide, perfume, water were added and blended well. The mixture was cooled to 30°C and 0.4g of Parsol 1789 and 1.2g of Parsol MCX dissolved in 2g of mineral oil was homogenised with the rest of the formulation.
Conventional Process:
60g of water and 0.48g of potassium hydroxide was taken in the main mixer. 16g of stearic acid, 0.15g propyl paraben
0.2g of silicone and 4.4g of Isopropyl palmitate was blended and heated to 70°C in a side vessel and in a portion of this mix the 0.4 g of Parsol 1789 and 1.2 g of Parsol MCX was dissolved. Both these mixtures were added into the main mixer under stirring and blended well . Other conventional ingredients, lg niacinamide, perfume, water to make to lOOg were added and mixed well by stirring.
Example 2 :
Spread and delivery of the sunscreens on the skin:
The forearms of 15 volunteers were washed with a soap and the surface was dabbed dry and the cream was applied half an hour later to ensure adequate and uniform drying of the forearms. Areas of 2 cm X 3 cm each using a template were marked. 30 mg of cream was applied using a glass rod with adequate care to spread it only inside the markings. Impressions of the experimental regions was taken individually using a cellophane tape from a dispenser with sufficient care not to smudge the surfaces . The tapes were placed on a frame . The different treatments were as follows. Example 2a: Cream containing no sunscreen or niacinamide
(placebo) Example 2b: Creams prepared by the conventional process described above where in the sunscreens
(Parsol 1789 at 0.4% and Parsol MCX were at 1.2% by weight of the composition) and the Niacinamide level was 1.0%.
Example 2c : Creams prepared as in Example 2b but containing double the level of sunscreens
(Parsol 1789 at 0.8% and Parsol MCX at 2.4% by weight of the composition) and niacinamide at 2.0%.
Example 2d: Creams prepared according to the invention as described above in which sunscreens (Parsol 1789 at 0.4% and Parsol MCX at 1.2% by weight of the composition) dissolved in mineral oil was added. Niacinamide at 1.0% was added.
Determination of uniformity of spread of the cream:
The frame with tapes was placed on a UV source such that the sticky surface of the tape faces downwards. A UV filter was placed over the source to ensure a UV light of constant intensity in the range of 240-350 nm. was obtained. A thin uniform film of a fluorescent dye CBS-X which has an absorption maximum of 368 nm and emission maximum of 406 and 426 nm, as a 2% solution in 1:1 gycerol :water was taken between two cover slips and placed on the non glue side of the tape. This enabled the emission of a visible light wherever there was UV light coming through the tape which was picked up by the video camera with a macroscopic lens (6X) was used. Thus wherever sunscreen was present UV light would be blocked and the fluorescer would not be excited thus giving a black area. The video camera was connected to a computer with a frame grabber card and using this images were stored. Using the Optimas image analysis software it was possible to quantify the difference in the amount of UV light passing through the tape. The lesser the intensity the better will be the UV blockage and thus better sunscreen efficacy. In addition, to macrophotography and intensity measurement using advanced image analysis techniques, the actual amount of UV A and UV B transmitted was also measured using specific probes for UV A and UV B.
The Table 1 shows that the efficacy of sunscreen in the formulation prepared according to the invention will be superior to creams prepared by the conventional process and is comparable to creams having double the amount of sunscreen in a formulation prepared according the conventional process.
Table 1
Figure imgf000011_0001
Example 3
In vivo skin lightening data:
20 Volunteers were selected who applied 0.75g of the cream prepared according to the invention (2d) , or creams prepared according to the conventional process (2b) or the placebo (2a) on one of their forearms twice daily. The other forearm was maintained as unapplied control . The skin tone was evaluated on a 10 point scale one day prior to the application and after 8 weeks of application. The data presented in Table 2 is a change in the score after 8 weeks of application. A negative score indicates a lighter skin tone as compared to the control and a positive score indicates darker skin tone as compared to the control.
Table 2
Figure imgf000012_0001
Example 4
The following creams were fielded in a double blind skin lightening clinical trial. 20 volunteers were selected who applied 0.75 g of creams prepared according to the invention as described in example 1 but using 2% isopropyl myristate (instead of mineral oil) as the oil phase (3a) , or creams prepared according to the conventional process (2b) , on one of their forearms twice daily. The other forearm was maintained as unapplied control. The skin tone was visually evaluated on a 10 point scale one day prior to application and after 8 weeks of application. The data presented in Table 3 is a change in the score after 8 weeks of application. A negative score indicates a lighter skin tone as compared to the control .
Table 3
Trial 1 Trial 2
Figure imgf000013_0001

Claims

1. A process for preparing a sunscreen composition comprising the steps of:
(i) dissolving 0.1 to 10% by weight of the composition of an ultraviolet radiation absorbing sunscreen in an oil phase;
(ii) neutralising stearic acid in a water phase; and
(iii) homogenising the dissolved sunscreen with the neutralised stearic acid and a cosmetically acceptable vehicle.
2. A process according to claim 1 wherein the dissolved sunscreen is homogenised with the neutralised stearic acid and cosmetically acceptable vehicle after the neutralised stearic acid and cosmetically acceptable vehicle have been homogenised.
3. A process according to claim 1 or 2 comprising the additional step of melting the stearic acid at a temperature above 70 °C prior to step (ii) .
4. A process according to any preceding claim wherein the oil phase is isopropyl myristate.
5. A topical cosmetic sunscreen composition obtainable by the process according to any preceding claim.
PCT/EP1999/008322 1998-12-16 1999-10-21 Sunscreen composition Ceased WO2000035414A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020017007506A KR20010089579A (en) 1998-12-16 1999-10-21 Sunscreen Composition
JP2000587735A JP2002532402A (en) 1998-12-16 1999-10-21 Sunscreen composition
AU16509/00A AU746501B2 (en) 1998-12-16 1999-10-21 Sunscreen composition
BR9916226-1A BR9916226A (en) 1998-12-16 1999-10-21 Process for preparing a sunscreen composition, and topical cosmetic composition of sunscreen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9827703.1 1998-12-16
GBGB9827703.1A GB9827703D0 (en) 1998-12-16 1998-12-16 Sunscreen composition

Publications (1)

Publication Number Publication Date
WO2000035414A1 true WO2000035414A1 (en) 2000-06-22

Family

ID=10844338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008322 Ceased WO2000035414A1 (en) 1998-12-16 1999-10-21 Sunscreen composition

Country Status (9)

Country Link
JP (1) JP2002532402A (en)
KR (1) KR20010089579A (en)
CN (1) CN1165281C (en)
AU (1) AU746501B2 (en)
BR (1) BR9916226A (en)
GB (1) GB9827703D0 (en)
ID (1) ID29804A (en)
WO (1) WO2000035414A1 (en)
ZA (1) ZA200104664B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015739A1 (en) * 2001-08-14 2003-02-27 Unilever Plc Dual compartment packaged cosmetic composition

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173108B2 (en) * 2009-11-04 2012-05-08 Conopco, Inc. Sunscreen composition
JP2023077885A (en) * 2021-11-25 2023-06-06 日油株式会社 SPF improver

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1370236A (en) * 1972-01-11 1974-10-16 Unilever Ltd Skin composition
EP0013390A2 (en) * 1978-12-19 1980-07-23 Dragoco, Inc. Cosmetic stick composition
US4840788A (en) * 1986-07-15 1989-06-20 Ici Americas Inc. Nonalcoholic sunscreen gel
EP0396422A1 (en) * 1989-05-05 1990-11-07 Unilever Plc Skin composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1370236A (en) * 1972-01-11 1974-10-16 Unilever Ltd Skin composition
EP0013390A2 (en) * 1978-12-19 1980-07-23 Dragoco, Inc. Cosmetic stick composition
US4840788A (en) * 1986-07-15 1989-06-20 Ici Americas Inc. Nonalcoholic sunscreen gel
EP0396422A1 (en) * 1989-05-05 1990-11-07 Unilever Plc Skin composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015739A1 (en) * 2001-08-14 2003-02-27 Unilever Plc Dual compartment packaged cosmetic composition
US6939552B2 (en) 2001-08-14 2005-09-06 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Dual compartment packaged cosmetic composition

Also Published As

Publication number Publication date
BR9916226A (en) 2001-10-02
CN1330535A (en) 2002-01-09
CN1165281C (en) 2004-09-08
ID29804A (en) 2001-10-11
AU1650900A (en) 2000-07-03
GB9827703D0 (en) 1999-02-10
JP2002532402A (en) 2002-10-02
ZA200104664B (en) 2002-06-07
KR20010089579A (en) 2001-10-06
AU746501B2 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
CN100566713C (en) Use of amino-substituted hydroxybenzophenones as photostable UV filters in cosmetic and pharmaceutical preparations
DE60105544T2 (en) Dyeing composition, method for the preparation and use for coloring the skin and / or the keratin fibers
CN1228039C (en) Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology
KR101823036B1 (en) Inhibitor of melanin synthesis and the cosmetic composition containing the same
EP0396422B1 (en) Skin composition
EP2217199B1 (en) Self-tanning effects
CA2705573C (en) Skin lightening compositions comprising arbutin
MX2012014074A (en) Microspheres and photoprotective personal care composition comprising same.
US20250275904A1 (en) Anti-sun cosmetic composition containing mycosporine-like amino acids
JP2018515486A (en) Method for improving skin appearance using nicotinamide riboside and composition therefor
EP1430016B1 (en) 3,4,5-trimethoxy phenyl-based ester compound and preparation method thereof and whitening cosmetic composition containing the same
JPH08507542A (en) Cosmetic composition for artificial tanning of the skin
AU746501B2 (en) Sunscreen composition
US6309626B1 (en) Sunscreen composition
US5554374A (en) Skin preparation using nanospheres
JP2986966B2 (en) Melanin production inhibitor
EP0585018A1 (en) Cosmetic composition for coloring hair and skin and for UV-protection
JP2001131072A (en) Use of DHEA or a precursor or metabolic derivative thereof as a depigmenting agent
DE60311627T2 (en) Agent for dyeing human keratin material containing at least two components and staining methods
JPH06279257A (en) Melanin biosynthesis inhibitor
JP2004002356A (en) Color-changing cosmetic and cosmeticizing method using the same cosmetic
JP2015522047A (en) Photoprotective personal care composition
MXPA01006117A (en) Sunscreen composition
JP3527406B2 (en) Skin whitening external preparation
JPH07196466A (en) Cosmetic composition formulated with tea powder

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814396.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 16509

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001/04664

Country of ref document: ZA

Ref document number: 16509/00

Country of ref document: AU

Ref document number: 200104664

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2000 587735

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006117

Country of ref document: MX

Ref document number: 1020017007506

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase